Anti-MINA RIOX2 Antibody

MINA is nuclear localized, myc-inducible protein that is thought to play a role in mammalian cell proliferation. Treatment of cancer cells lines such as the colon cancer cell line SW680 with siRNA against MINA inhibits cell growth, demonstrating that MINA may be a potential therapeutic target. MINA regulates several genes related to cell adhesion and metabolism that have also been shown to be regulated by c-Myc, but also regulates other genes whose expression are not modulated by c-Myc such as EGFR, IL-6 and HGF. MINA has also been found to act as a repressor to IL-4 expression in T cells, indicating that it may also play a role in T cell differentiation and genetic variation in T helper type 2 bias.

MINA antibody was raised against a 15 amino acid synthetic peptide near the amino terminus of human MINA. The immunogen is located within amino acids 380 - 430 of MINA.

Expressed in liver, skeletal muscle, heart, pancreas, and placenta. Not detected in brain, lung or kidney. Expressed in several lung cancer tissues, but is barely detected in the adjacent non-cancerous tissues. Also highly expressed in several esophageal squamous cell carcinoma (ESCC), and colon cancer tissues, and in various cancer cell lines.

Oxygenase that can act as both a histone lysine demethylase and a ribosomal histidine hydroxylase. Is involved in the demethylation of trimethylated 'Lys-9' on histone H3 (H3K9me3), leading to an increase in ribosomal RNA expression. Also catalyzes the hydroxylation of 60S ribosomal protein L27a on 'His-39'. May play an important role in cell growth and survival. May be involved in ribosome biogenesis, most likely during the assembly process of pre-ribosomal particles.

MINA antibody can be stored at 4°C for three months and -20°C, stable for up to one year. Avoid repeated freeze-thaw cycles. Antibodies should not be exposed to prolonged high temperatures.